Skip to main content
. 2020 Jul 9;14:1753466620938553. doi: 10.1177/1753466620938553

Key points (5).

• From a wide set of integrated data, larotrectinib has demonstrated an elevated efficiency in diverse tumors, achieving 81% ORR and a complete response of 17%.
• Of the patients with NTRK fusions treated with larotrectinib, 9% required a reduction of the dose. All maintained a tumor regression.
• Less than 1% of the patients with NTRK fusion suspended larotrectinib due to the presentation of an adverse event.